Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study
Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study
Precision healthcare aims to tailor disease prevention and early detection to individual risk. Prostate cancer screening may benefit from genomics-informed approaches. We developed and validated the P-CARE model, a prostate cancer risk prediction tool combining a polygenic score, family history and genetic ancestry, using data from over 585,000 male participants in the Million Veteran Program.
The model was externally validated in diverse cohorts and implemented via a blended genome–exome assay for clinical use. Here we show that the P-CARE model identifies clinically meaningful gradients of prostate cancer risk among men, with higher scores associated with increased risk of any, metastatic and fatal prostate cancer. The model is now being used in a clinical trial of precision prostate cancer screening. This work demonstrates the potential for genomics-enabled health systems to improve prostate cancer screening and prevention in men. ClinicalTrials.gov registration: NCT05926102.
352-367
Eccles, Diana M.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Townsend, Paul A.
54e7bb11-feba-4886-b792-ab0f93c9c734
February 2026
Eccles, Diana M.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Townsend, Paul A.
54e7bb11-feba-4886-b792-ab0f93c9c734
Vassy, J.L., Dornisch, A.M. and Karunamuni, R.
,
et al
(2026)
Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study.
Nature Cancer, 7 (2), .
(doi:10.1038/s43018-025-01103-0).
Abstract
Precision healthcare aims to tailor disease prevention and early detection to individual risk. Prostate cancer screening may benefit from genomics-informed approaches. We developed and validated the P-CARE model, a prostate cancer risk prediction tool combining a polygenic score, family history and genetic ancestry, using data from over 585,000 male participants in the Million Veteran Program.
The model was externally validated in diverse cohorts and implemented via a blended genome–exome assay for clinical use. Here we show that the P-CARE model identifies clinically meaningful gradients of prostate cancer risk among men, with higher scores associated with increased risk of any, metastatic and fatal prostate cancer. The model is now being used in a clinical trial of precision prostate cancer screening. This work demonstrates the potential for genomics-enabled health systems to improve prostate cancer screening and prevention in men. ClinicalTrials.gov registration: NCT05926102.
This record has no associated files available for download.
More information
Accepted/In Press date: 24 November 2025
e-pub ahead of print date: 26 January 2026
Published date: February 2026
Identifiers
Local EPrints ID: 511261
URI: http://eprints.soton.ac.uk/id/eprint/511261
ISSN: 2662-1347
PURE UUID: f09bf11b-c60c-4763-8435-d4d6090134b1
Catalogue record
Date deposited: 11 May 2026 16:33
Last modified: 12 May 2026 01:33
Export record
Altmetrics
Contributors
Author:
Paul A. Townsend
Author:
J.L. Vassy
Author:
A.M. Dornisch
Author:
R. Karunamuni
Corporate Author: et al
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
